Patient and other factors influencing the prescribing of cardiovascular prevention therapy in the general practice setting with and without nurse assessment

Medical Decision Making

Volumn 32, Issue 3, 2012, Pages 498-506

  Mohammed, Mohammed A ^a   El Sayed, Charlotte ^a   Marshall, Tom ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

cardiovascular disease; cardiovascular risk; general practice; nurse assessment; Prescribing; risk factors

Indexed keywords

ANTIHYPERTENSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CONFIDENCE INTERVAL; DECISION MAKING; DOCTOR PATIENT RELATION; FEMALE; GENERAL PRACTITIONER; HUMAN; INTERPERSONAL COMMUNICATION; MALE; MIDDLE AGED; NURSING; NURSING DIAGNOSIS; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; RISK; RISK ASSESSMENT; STATISTICAL MODEL; STATISTICS; UNITED KINGDOM;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; COMMUNICATION; CONFIDENCE INTERVALS; DECISION MAKING; ENGLAND; FEMALE; GENERAL PRACTITIONERS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; MIDDLE AGED; NURSING DIAGNOSIS; ODDS RATIO; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIAN-PATIENT RELATIONS; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; RISK ASSESSMENT;

EID: 84861823591     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X12437246     Document Type: Article

References (49)

1. Report of Inter-Society Commission for Heart Disease Resources: III. Cardiovascular disease-long-term care. Guidelines for the detection, diagnosis and management of hypertensive populations. Circulation. 1971 ; 44 (5). A263-72
2. Prevention of coronary heart disease. Report of a joint working party of the Royal College of Physicians of London and the British Cardiac Society. J R Coll Physicians. 1976 ; 10 (3). 237-42
3. Guidelines for the treatment of mild hypertension: memorandum from a WHO/ISH meeting. Bull World Health Org. 1983 ; 61 (1). 53-6
4. Evaluation and Treatment of High Blood Pressure. Arch Intern Med. 1980 1280 ; 140 :
5. Guidelines in the management of hypertension in general practice: detection and assessment of hypertension. J R Coll Gen Pract. 1984 ; 7: 405-7
6. Shepherd J, Betteridge DJ, Durrington P, et al. Strategies for reducing coronary heart disease and desirable limits for blood lipid concentrations: guidelines of the British Hyperlipidaemia Association. Br Med J. 1987 ; 295: 1245-6
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med. 1988 ; 148: 36-69
8. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2003 ; 24: 1601-10
9. National Institute for Clinical Excellence. Hypertension management of hypertension in adults in primary care [clinical guideline 18]. http://www.nice.org.uk/CG018NICEguidelinePublished 2004. Accessed July 26, 2009.
10. Cooper A Nherera L Calvert N. Clinical guidelines and evidence review for lipid modification: cardiovascular risk assessment and the primary and secondary prevention of cardiovascular disease. http://guidance.nice.org.uk/ CG67. Published 2008. Accessed July 26, 2009.
11. JBS 2: joint British societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005 ; 91: 1-52
12. Anderson KM, Odell PM, Silson PWF, Kannel WB. Cardiovascular disease risk profiles. Amer Heart J. 1991 ; 121: 293-8
13. Christian A, Millls T, Simpson S, Mosca L. Quality of cardiovascular disease preventive care and physician/practice characteristics. J Gen Intern Med. 2006 ; 21 (3). 231-7
14. McBride P, Schrott H, Plane M, Underbakke G, Brown R. Primary care practice adherence to national cholesterol education program guidelines for patients with coronary heart disease. Arch Intern Med. 1998 ; 158 (11). 1238-44
15. Ohlsson H, Merlo J. Is physician adherence to prescription guidelines a general trait of health care practices or dependent on drug type? A multilevel logistic regression analysis in south Sweden. Pharmacoepidemiol Drug Saf. 2009 ; 18 (8). 682-90
16. Erhardt LR, Hobbs FD. A global survey of physicians' perceptions on cholesterol management: the From the Heart study. Int J Clin Pract. 2007 ; 61 (7). 1078-85
17. Roumie CL, Elasy TA, Wallston KA, et al. Clinical inertia: a common barrier to changing provider prescribing behavior. Jt Comm J Qual Patient Saf. 2007 ; 33 (5). 277-85
18. Martino M, Esposti L, Ruffo P, et al. Underuse of lipid-lowering drugs and factors associated with poor adherence: a real practice analysis in Italy. Eur J Clin Pharmacol. 2005 ; 61: 225-30
19. Whincup H, Emberson J, Lennon L, Papacosta O, Thomson A. Low prevalence of lipid lowering drug use in older men with established coronary heart disease. Heart. 2002 ; 88: 25-9
20. Van Duijn H, Belo JN, Blom JW, Velberg ID, Assendelft WJJ. Revised guidelines for cardiovascular risk management: time to stop medication: a practice based intervention study. Br J Gen Pract. 2011 ; 61: e347-52
21. Abookire SA, Karson AS, Fiskio J, Bates DW. Use and monitoring of "statin" lipid-lowering drugs compared with guidelines. Arch Intern Med. 2001 ; 161: 53-8
22. Tonstad S, Rosvold EO, Furu K, Skurtveit S. Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001. J Intern Med. 2004 ; 255: 494-502
23. Furberg CD, Berglund G, Manolio TA, Psaty BM. Overtreatment and undertreatment of hypertension. J Intern Med. 1994 ; 235 (5). 387-97
24. Myers MG, Reeves RA, Oh PI, Joyner CD. Overtreatment of hypertension in the community?. Amer J Hypertens. 1996 ; 9: 419-25
25. Arroll B, Jenkins S, North D, Kearns R. Management of hypertension and the core services guidelines: results from interviews with 100 Auckland general practitioners. N Z Med J. 1995 ; 108: 55-7
26. Backlund L, Skaner Y, Montgomery H, Bring J, Strender L. GPs' decisions on drug treatment for patients with high cholesterol values: a think-aloud study. BMC Med Inform Decis Mak. 2004 ; 4: 23
27. Roncaglioni M, et al. How general practitioners perceive and grade the cardiovascular risk of their patients. Eur J Cardiovasc Prev Rehabil. 2004 ; 11 (3). 233-8
28. Vancheria F, Strender LE, Montgomery H, Skånér Y, Backlund LG. Coronary risk estimates and decisions on lipid-lowering treatment in primary prevention: Comparison between general practitioners, internists, and cardiologists. Eur J Intern Med. 2009 ; 20 (6). 601-6
29. Montgomery AA, Fahey T, MacKintosh C, Sharp DJ, Peters TJ. Estimation of cardiovascular risk in hypertensive patients in primary care. Br J Gen Pract. 2000 ; 451 (2). 127-8
30. Graham IM, Stewart M, Hertog MG. Factors impeding the implementation of cardiovascular prevention guidelines: findings from a survey conducted by the European Society of Cardiology. Eur J Cardiovasc Prev Rehabil. 2006 ; 13 (5). 839-45
31. Marshall T, Westerby P, Chen J, Fairfield M, Harding J. The Sandwell Project: a controlled evaluation of a programme of targeted screening for prevention of cardiovascular disease in primary care. BMC Public Health. 2008 ; 8: 73
32. Marshall T, Westerby P, Chen J, Fairfield M, Harding J. The Sandwell Project: a controlled evaluation of a programme of targeted screening for prevention of cardiovascular disease in primary care. BMC Public Health. 2008 ; 8: 73
33. Marshall T. Identification of patients for clinical risk assessment by prediction of cardiovascular risk using default risk factor values. BMC Public Health. 2008 ; 8: 25
34. Midlöv P, Ekenbo R, Johansson L, et al. Barriers to adherence to hypertension guidelines among GPs in south Sweden: a survey. Scand J Prim Health Care. 2008 ; 26 (3). 154-9
35. Persson M, Carlberg B, Tavelin B, Lindholm LH. Doctors' estimation of cardiovascular risk and willingness to give drug treatment in hypertension: fair risk assessment but defensive treatment policy. J Hypertens. 2004 ; 22 (1). 65-71
36. Wassenberg MWM, Willemsen JM, Gaillard CA, Braam B. Hypertension management in primary care: standard care and attitude towards a disease management model. Neth J Med. 2004 ; 62 (10). 375-82
37. Vaur L, Amar J, Perret M, Bailleau C, Etienne S, Chamontin B. [Influence of cardiovascular risk factors on prescribing of antihypertensives] [French]. Archives des Maladies du Coeur et des Vaisseaux. 2001 ; 94 (8). 846-50
38. Ma J, Sehgal N, Ayanian J, Stafford R. National trends in statin use by coronary heart disease risk category. PLoS Med. 2005 ; 2 (5). 434-40
39. Mantel-Teeuwisse AK, Verschuren WMM, Klungel OH, et al. Undertreatment of hypercholestrolaemia: a population-based study. Br J Clin Pharmacol. 2003 ; 55: 389-97
40. Wood DA, Kotseva K, Connolly S, et al. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. Lancet. 2008 ; 371 (9629). 1999-2012
41. Voogdt-Pruis HR, Beusmans GH, Gorgels AP, Kester AD, van Ree JW. Effectiveness of nurse-delivered cardiovascular risk management in primary care: a randomised trial. Br J Gen Pract. 2010 ; 60 (570). 40-6
42. Caruana E. Effectiveness of general practice nurse interventions in cardiac risk factor reduction among adults. J Adv Nurs. 2008 ; 62 (5). 530-1
43. Petursson H, Getz L, Sigurdsson JA, Hetlevik I. Current European guidelines for management of arterial hypertension: are they adequate for use in primary care? Modelling study based on the Norwegian HUNT 2 population. BMC Fam Pract. 2009 ; 10: 70
44. Getz L, Sigurdsson JA, Hetlevik I. Is opportunistic disease prevention in the consultation ethically justifiable?. BMJ. 2003 ; 327 (7413). 498-500
45. Gumbs PD, Verschuren WM, Mantel-Teeuwisse AK, et al. Drug costs associated with non-adherence to cholesterol management guidelines for primary prevention of cardiovascular disease in an elderly population: the Rotterdam study. Drugs Aging. 2006 ; 23 (9). 733-41
46. Bryan S, Gill P, Greenfield S, Gutridge K, Marshall T. Predictors of patients' preferences for treatments to prevent heart disease. Heart. 2006 ; 92: 1651-5
47. Montgomery AA, Harding J, Fahey T. Shared decision making in hypertension: the impact of patient preferences on treatment choice. Fam Pract. 2001 ; 18 (3). 309-13
48. Bryan S, Gill P, Greenfield S, Gutridge K, Marshall T. The myth of agency and patient choice in health care? The case of drug treatments to prevent coronary disease. Soc Sci Med. 2006 ; 63: 2698-701
49. Prochaska JO, DiClemente CC. Stages and processes of selfchange of smoking: toward an integrative model of change. J Consult Clin Psychol. 1983 ; 51: 390-5